Lidocaine - MGI GP
Alternative Names: Lidocaine controlled-release; Lidocaine microspheres; Lidocaine-PELatest Information Update: 20 Jan 2022
At a glance
- Originator MGI GP
- Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
- Mechanism of Action Cell membrane permeability inhibitors; Opioid receptor agonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postoperative pain
Most Recent Events
- 28 Oct 2005 Guilford Pharmaceuticals is now called MGI GP Inc
- 31 Dec 2002 Discontinued - Phase-I for Postoperative pain in Europe (Injection)
- 08 Aug 2002 Guilford Pharmaceuticals is seeking a partner for the development of lidocaine formulation